While Aurobindo Pharma did not mention any specific media report on its acquisition, ET.com on Wednesday reported, citing sources, that the company has emerged as the frontrunner to acquire Zentiva, a Prague-based generic drugmaker, for $5 billion – $5.5 billion from Advent International.
